Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Alzheimer's disease biological domain sub-stratification enhances the precision of functional analyses.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mapping cross-domain drivers of Alzheimer's disease risk through integrated network analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Taming the "death receptor": translating the first-in-class p75<sup>NTR</sup> modulator LM11A-31 from basic biology, across broad preclinical models, to clinical proof-of-concept.

Journal of translational medicine·2026
Same author

Trends and Risk Factors in Revision and Re-Revision Total Hip Arthroplasty in Medicare Patients from 2016 to 2022.

The Journal of arthroplasty·2026
Same author

Small molecule modulation of the p75 neurotrophin receptor promotes dendritic spine resilience to pathogenic tau species and reduces their accumulation.

Acta neuropathologica communications·2026
Same author

Culturally Responsive Mental Health Care for Asian Americans: A Call to Action.

Harvard review of psychiatry·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Robert R Butler1, Tao Yang1, Crystal Han1

  • 1Stanford University, Stanford, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

El tratamiento con LM11A-31 (C31) en modelos de tauropatía revierte parcialmente la comunicación neuronal-glial alterada al modular la señalización de Apoe y la actividad de los receptores gliales. Esto sugiere que C31 tiene potencial terapéutico para enfermedades neurodegenerativas.

Palabras clave:
tauropatíasneurodegeneracióncomunicación neuronal-glialLM11A-31desarrollo de fármacostranscriptómica espacialsnRNA-seqastrocitosmicroglíaenfermedad de Alzheimer

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia
  • Biología Molecular
  • Genética

Sus antecedentes:

  • La patología Tau impulsa la neurodegeneración en la Enfermedad de Alzheimer (EA).
  • LM11A-31 (C31), un modulador del receptor de neurotrofinas p75 (p75NTR), reduce la acumulación de tau y el daño sináptico.
  • El impacto de C31 en la comunicación neuronal-glial no se comprende completamente.

Objetivo del estudio:

  • Investigar los efectos a largo plazo de C31 en la comunicación sináptico-glial en la tauropatía.
  • Utilizar la secuenciación de ARN de núcleo único (snRNA-seq) y la transcriptómica espacial para analizar las interacciones neuronales-gliales.

Principales métodos:

  • Se administró C31 o vehículo a ratones Tau P301S (PS19) y de tipo salvaje (Wt) durante 3 meses.
  • Se realizó snRNA-seq e imagen molecular espacial CosMx en la corteza del ratón.
  • Se analizaron las interacciones célula a célula utilizando Liana para interacciones ligando-receptor (LR).

Principales resultados:

  • Los astrocitos y la microglía mostraron interacciones LR dependientes del genotipo/fármaco con neuronas glutamatérgicas.
  • Las células gliales recibieron señalización de Apoe de las neuronas a través de receptores de lipoproteínas, elevados en ratones PS19 pero reducidos por C31.
  • Los astrocitos mostraron una señalización enriquecida de la matriz extracelular; la microglía mostró una actividad LR alterada que involucra al co-receptor p75NTR Sort1 y Ntrk2.

Conclusiones:

  • La tauropatía altera la comunicación neuronal-glial.
  • El tratamiento con C31 mejora este diálogo cruzado, potencialmente a través de la participación directa de la microglía.
  • C31 muestra potencial terapéutico para enfermedades neurodegenerativas al influir en la integridad sináptica y la comunicación glial.